SCHEMBL3159127

SCHEMBL3159127

O=C(NCc1c(F)cccc1Cl)c1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 5/20 0.66
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
ALOX12 P18054 2/20 0.54
PDE4A P27815 1/20 0.52
PDE7A Q13946 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 1/20 0.51
ALDH1A1 P00352 4/20 0.51
CA1 P00915 1/20 0.51
SCN1A P35498 1/20 0.50
KCNH2 Q12809 1/20 0.50
SCN5A Q14524 1/20 0.50
SCN9A Q15858 1/20 0.50
SCN2A Q99250 1/20 0.50
SCN8A Q9UQD0 1/20 0.50
SCN10A Q9Y5Y9 1/20 0.50
PKM P14618 1/20 0.50
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3168433 0.93 SCN3A (0.72) SCN3AMEN1KMT2AALOX12SMN1; SMN2
SCHEMBL3165573 0.87 SCN3A (0.67) SCN3AMEN1KMT2AALOX12SMN1; SMN2
SCHEMBL3167932 0.86 SCN3A (0.67) SCN3AMEN1KMT2AALOX12SMN1; SMN2
SCHEMBL3163449 0.84 SCN3A (0.68) SCN3AMEN1KMT2AALOX12SMN1; SMN2
SCHEMBL3154212 0.84 SCN3A (0.74) SCN3AMEN1KMT2AALOX12SMN1; SMN2
SCHEMBL3169548 0.83 SCN3A (0.66) SCN3AMEN1KMT2AALOX12SMN1; SMN2
SCHEMBL3160099 0.83 SCN3A (0.63) SCN3AMEN1KMT2AALOX12SMN1; SMN2
SCHEMBL3163272 0.83 SCN3A (0.75) SCN3AMEN1KMT2AALOX12SMN1; SMN2
SCHEMBL3161195 0.81 SCN3A (0.63) SCN3AMEN1KMT2AALOX12SMN1; SMN2
SCHEMBL3168852 0.80 SCN3A (0.77) SCN3AMEN1KMT2AALOX12SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885MEN1 4729/4885KMT2A 1920/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885MEN1 4729/4885KMT2A 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.